

FALL 2017 Volume 20 | Issue 4

# Impact

dana-farber.org and jimmyfund.org

THANKING THOSE WHO MAKE A DIFFERENCE



## Tina's Wish grants focus on early detection of ovarian cancer


Only 20 percent of women with ovarian cancer are diagnosed at an early stage when more successful treatment options are available, according to the American Cancer Society. Dana-Farber's Dipanjan Chowdhury, PhD, and Jarrod Marto, PhD, have been awarded grants totaling \$300,000 from The Honorable Tina Brozman Foundation, also known as "Tina's Wish," to pursue innovative research on the early detection of ovarian cancer.

With his grant, Chowdhury hopes to develop a blood test that could possibly detect ovarian cancer at an early stage, using extremely small microRNA molecules that can form a "signature" in blood serum and distinguish early ovarian malignancies from benign tumors.

Marto, director of Dana-Farber's Blais Proteomics Center, is using protein measurement technology developed in his laboratory to drive the discovery of new protein biomarkers for ovarian cancer, which also may aid early diagnosis.

Tina's Wish funds ground-breaking research on the early detection and prevention of ovarian cancer in memory of Tina Brozman, a former chief judge of the U.S. Bankruptcy Court for the Southern District of New York who died of ovarian cancer in 2007.

"I think Tina would be extraordinarily gratified by what we've achieved in her honor," said Andrew Brozman, Tina's husband and Tina's Wish board member. "We are excited to be funding eight grantees from top institutions in 2017/18, including Dana-Farber Cancer Institute. I am confident that we are supporting the most innovative science out there." ■



Jarrod Marto, PhD, addresses the audience at the Tina's Wish Boston Gathering in March 2017.